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a  b  s  t  r  a  c  t
Converging  lines  of evidence  suggest  that  the  pathophysiology  of pain  is  mediated  to a substantial  degree
via  allostatic  neuroadaptations  in  reward-  and  stress-related  brain  circuits.  Thus,  reward  deﬁciency  (RD)
represents  a  within-system  neuroadaptation  to pain-induced  protracted  activation  of  the  reward  circuits
that leads  to depletion-like  hypodopaminergia,  clinically  manifested  anhedonia,  and  diminished  motiva-
tion  for  natural  reinforcers.  Anti-reward  (AR)  conversely  pertains  to a between-systems  neuroadaptation
involving  over-recruitment  of key  limbic  structures  (e.g., the central  and  basolateral  amygdala  nuclei,  the
bed nucleus  of  the  stria  terminalis,  the  lateral  tegmental  noradrenergic  nuclei  of  the  brain  stem,  the hip-
pocampus  and  the  habenula)  responsible  for massive  outpouring  of stressogenic  neurochemicals  (e.g.,
norepinephrine,  corticotropin  releasing  factor,  vasopressin,  hypocretin,  and  substance  P) giving  rise to
such  negative  affective  states  as  anxiety,  fear  and  depression.  We  propose  here  the  Combined  Rewardmygdala
abenula
ucleus accumbens
opamine
ddiction
tress
deﬁciency  and Anti-reward  Model  (CReAM),  in which  biopsychosocial  variables  modulating  brain  reward,
motivation  and  stress  functions  can interact  in  a  ‘downward  spiral’  fashion  to exacerbate  the  intensity,
chronicity  and  comorbidities  of chronic  pain  syndromes  (i.e.,  pain  chroniﬁcation).
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ain
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. Introduction
Critical for the survival of organisms, pain is also a reason why
ives of so many people become plainly unbearable. In addition to
remendous personal suffering, pain exerts an enormous economic
oll on patients, their families and society as a whole. It is reported
o afﬂict over 100 million Americans, costing an estimated $600
illion annually (Gaskin and Richard, 2012) due to the loss of pro-
uctivity, medical expenses, and long-term disability (Institute of
edicine (IOM), 2011 http://iom.nationalacademies.org/reports/
011/relieving-pain-in-america-a-blueprint-for-transforming-
revention-care-education-research.aspx). Over 25 million Amer-
cans experience daily pain (Nahin, 2015). The fact that these
umbers are steadily rising (Freburger et al., 2009), in spite of the
verall improving standards of health care, emphasizes the urgent
eed for novel insights informing better diagnosis, prevention, and
reatment of pain patients.
Documented attempts to understand pain and to counteract its
eleterious effects date back to the earliest accounts of written
uman history. Yet, the relative inefﬁcacy of the currently avail-
ble pharmacological agents (Backonja et al., 1998; McNicol et al.,
013; Skljarevski et al., 2009), even when administered in combi-
ation (Gilron et al., 2005), renders pain one of the most challenging
roblems faced by modern medicine. The International Association
or the Study of Pain (IASP) deﬁnes pain as an “emotional experi-
nce associated with actual or potential tissue damage,” thus pointing
o affective neuroscience as promising direction for tackling this
onundrum. However, while the involvement of the central ner-
ous system in pain is well recognized, there is still a gap between
emarkable basic discoveries and their translation into understand-
ng of clinical symptomatology, and into mechanistically informed
herapeutic interventions for chronic pain syndromes (deﬁned as
onger than 12 weeks duration; National Institutes of Health, 2011).
In addition to various genetic, epigenetic (Crow et al., 2013),
nd environmental factors (Shutty et al., 1992), interpersonal vari-
bility in the engagement of emotional corticolimbic circuitry by
ain may  explain why some patients develop chronic pain condi-
ions and others do not. This is supported by consistent ﬁndings
f chronic painful symptoms in stress-related mood and anxiety
isorders. For instance, the vast majority (up to 80%) of patients
ith Major Depressive Disorder (MDD) reports comorbid pain
onditions (Leuchter et al., 2010). Additionally, pre-surgical pain
atastrophizing scores have been shown to predict the severity
f chronic post-surgical pain (Havakeshian and Mannion, 2013)
hilst the evolution of chronic pain depends, in part, on the
ropensity toward repeated engagement of corticolimbic stress
nd reward circuits (Apkarian et al., 2013; Baliki et al., 2012).
Here we discuss the role of neuropathological entities known
s ‘reward deﬁciency’ (RD) and “anti-reward” (AR), clinically evi-
ent in respectively decreased sensitivity to natural reinforcers
nd in stress-like negative affective states as valid components
f chronic pain. Chronic pain appears to impact both hedonic and
version related behaviors so that rewarding stimuli become less
ewarding, and aversive stimuli become more aversive. A paral- . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . .  .  . . . .  .  . .  . . .  .  .  .  . .  . . . . .  . . . . .  .  .  .  .  . .  .  .  .  .  .  . 294
lel may  be drawn to drug dependence, where patients over time
lose the initial “high” of a stimulant, and eventually “need drugs
just to be normal”, but such ‘normality’ may  become hard to bear
due to increased stress (Volkow et al., 2016). Similarly, in persis-
tent pain, the rewarding properties of pain relief may  diminish
over time and the averseness of uncontrolled pain and nega-
tive events becomes more and more overwhelming (Elman and
Borsook, 2016; Elman et al., 2011). These processes interact with
and are affected by functions in so called ‘classic pain circuitry’
in the central nervous system; regions involved in pain process-
ing include somatosensory (e.g., thalamus, primary somatosensory
cortex, posterior insula cortex), emotional (e.g., cingulate, basal
ganglia, amygdala, hippocampus) and descending modulatory con-
trol (e.g., periaqueductal gray) systems.
Chronic pain might be operationalized in distinct ways; how-
ever, the present approach offers several advantages. First, it has
deﬁned neuroanatomical and neurofunctional components (Blum
et al., 2012b; Elman et al., 2013). Second, it rests on ﬁrm clinical
research grounds i.e., RD and AR are involved in the centraliza-
tion of pain (See Box 1 for deﬁnition) which is theorized to play a
key role and contribute to comorbid aberrant emotional and cog-
nitive processing (Borsook et al., 2012; Bushnell et al., 2013; Elman
et al., 2013). Third, it attempts to model the unremitting course
of chronic pain that renders the innate homeostatic and pharma-
cological analgesic processes ineffective, leading to impairments
in normative compensatory mechanisms and shifting the set point
for the hedonic and sensory homeostasis towards the development
of refractory pain conditions accompanied by persistently negative
affective states (Elman et al., 2013).
The following text is divided into four sections containing:
(1) a brief summary of Pain and Reward Neurobiology; (2) Neu-
roanatomical and clinical manifestations of Reward Deﬁciency (RD)
and Anti-reward (AR) States in Chronic Pain along with the role of
(3) General Model of RD-AR in Pain Centralization/Chroniﬁcation
(see Fig. 1) and in its comorbidities; we have termed this model
Combined Reward Deﬁciency Antireward Model (CReAM) for
chronic pain; and ﬁnally (4) Treatment Opportunities in CReAM,
where the focus rests on the pharmacological, brain modulation
and psychological therapies informed by CReAM.
2. Pain and reward neurobiology
Any attempt to enhance our understanding regarding the brain
mechanisms underlying the transformation from health to chronic
pain faces a major challenge: how to operationalize such a com-
monplace condition that has been given as many explanations as
there are treatises that have dealt with it. The concept of a pain
connectome has recently emerged to encompass the multitude of
brain connections that constitute an altered state in chronic pain
(Kucyi and Davis, 2015). However, constraining such a connec-
tome to some core networks has proven difﬁcult, as the human
experience of pain can engage and modulate everything from
basic sensory perceptions to manifestations of culture (Elman and
Borsook, 2016). In a clinical context, some examples include the role
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Box 1: Deﬁnition of terms.
Allostasis:  attaining temporal stability in response to challenge via supraphysiological changes in systems that normally promote
homeostasis (McEwen and Stellar, 1993).
Allostatic load: the burden on the system with the consequent ‘wear and tear’ as a result of repeated and/or dysregulated allostatic
changes that acutely support an attempt for stabilization of regular function (McEwen and Stellar, 1993).
Anti-reward: a condition wherein interference with homeostatic functioning of the reward and reinforcement circuitry due to recurrent
stimulation by drugs and/or by pain triggers between-system adaptation, recruiting central and basolateral amygdala nuclei, the bed
nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brain stem, the hippocampus and the Hb that in concert
contribute to massive outpouring of stressogenic corticotropin-releasing factor, norepinephrine and dynorphin. This is manifested in
negative affective states, anhedonia and motivational states that are rigidly and exclusively focused on seeking drugs or on the relief
of pain.
Centralization of pain: the process by which the initial pain (e.g., injury) transforms to chronic pain with complex comorbid changes
including altered psychological status (anxiety, depression), addiction, altered reward and antireward function (see Borsook et al.,
2013c).
Central sensitization of pain: as a result of a nociceptive barrage, changes in sensitivity of the central pain/nociceptive pathways may
result in a prolonged and usually reversible increased in excitability to stimuli resulting in clinical manifestations of hypersensitivity
(viz., dynamic tactile allodynia, secondary punctate or pressure hyperalgesia, after-sensations, and enhanced temporal summation)
(Woolf, 2011).
Cross sensitization: a state when prior exposure to one stimulus (i.e., pain) increases subsequent response to a different stimulus
(e.g., stress, drugs, allergies or smell) and in the reversed order, e.g., enhancement of pain following prior stress exposure.
Denervation hypersensitivity: this is the state of supersensitive/enhanced response to a signal/neurotransmitter as a result of an
interrupted synaptic (input/receptor) activation or function.
Feed-forward interaction:  contrary to the negative feedback concept, positive feedback is an autonomous, self-sustaining feed-forward
loop wherein whereby a stimulus mounts escalating responses that are amplifying the original stimulus.
Habituation: the term is used to denote a decrease in a behavioral or physiological response to a repeated stimulus (e.g., drug,
painful).
Hedonic tone: the amount of pleasurable or positive feelings a person experiences at a given time point.
Homeostasis: in the context used here, it is the maintenance of a physiological equilibrium of the internal environment or function
in the face of external changes (e.g., stress, drugs etc).
Intervening variable: a subjective state that connects physiological necessities with motivations and ensuing behaviors.
Motivational/incentive salience: a “wanting” process by which an organism determines the motivational value of a particular object
beyond the emotional experience it evokes i.e., “liking.”
Opponent-proponent systems: a situation when a stimulus or an affective (i.e., proponent) process evokes an affective (opponent)
process of the reversed valence. The latter may be particularly apparent with the cessation of the former (e.g., a sense of euphoria
ensuing with termination of pain).
Pain: an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of
such damage (IASP; http://www.iasp-pain.org). Pain is considered to be a chronic condition when it lasts longer than 3 months.
Pain chroniﬁcation:  the process of maintenance of ongoing pain that may increase in severity over time. The process may  include
increased levels of depression or anxiety that contribute to maintenance or severity of pain.
Phasic and tonic dopamine release: tonic dopaminergic neurotransmission refers to the sustained release of dopamine due to
ongoing, background of neuronal activity whereas phasic dopaminergic transmission refers to the sudden release of dopamine due to
transient, spontaneous bursts of neuronal ﬁring, usually in response to a stimulus or an event (Grace, 1991, 1995; Jarcho et al., 2012).
Tonic ﬁring refers to spontaneously occurring baseline spike activity. Phasic activation of the DA system involves a burst-spike ﬁring
pattern and is dependent on glutamatergic excitatory synaptic drive onto DA neurons. Burst spike ﬁring triggers a high amplitude,
transient, phasic DA release intrasynaptically within the targeted areas (Floresco et al., 2003; Grace, 1995).
Primary and secondary hypodopaminergia: decreased dopamine levels due to an innate biological process/disease (primary) or as
a result of exogenous factors (secondary).
Pseudo-addiction:  the term describes drug-seeking behavior that occurs in a pain dependent manner (i.e., patients may  have inade-
quate pain treatment).
Reward-aversion continuum:  the ongoing subjective evaluation of pleasurable/rewarding and aversive processes; in the context of
pain it refers to pain relief (rewarding) vs. pain onset/presence/persistence (i.e., pain vs. analgesia).
Reinforcement: an increase in a likelihood of repeated action. In a biological context, rewards are associated with survival of individual
and species (e.g., obtaining food, water and sex).
Reward: any stimulus that is perceived as positive or pleasurable (Hyman and Malenka, 2001).
Reward-deﬁciency: diminution in the capacity to experience joy and pleasure along with paucity of drive and motivation arising in
the context of hypofunctionality of the brain circuits mediating reward, reinforcement and motivation (Comings and Blum, 2000; Elman
et al., 2009). The reward deﬁciency state may  have a genetic antecedent expressed in the dopamine D2 receptor polymorphisms (Blum
et al., 2013) rendering susceptible individuals to baseline or easily acquired reward deﬁciency. Chronic pain may result in alterations
in the reward cascade with subsequent increase in discomfort and inability to garner good feelings from normally rewarding stimuli.
The hallmarks of such maladaptations include anhedonia, numbing, apathy and decreased motivation for natural reinforcers.
Reward and reinforcement circuitry: comprised of an ‘in-series’ pathway linking the ventral tegmental area, NAc and ventral pallidum
via the medial forebrain bundle (Gardner, 2011).
Sensitization: pain-induced changes in the mesolimbic dopaminergic circuitry including dopamine terminal ﬁelds (e.g., striatum,
t pro
o
namygdala, and mPFC) underlying normal opponent and proponen
salience assigned to pain, analgesia and to related cues.f expectations and physician-patient interaction in placebo and
ocebo responses (Carlino and Benedetti, 2016), or the intrinsicallycesses that transform these processes into heightened incentiverewarding properties of pain relief (Becerra et al., 2001; Navratilova
et al., 2015).
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Fig. 1. Combined Reward Deﬁciency-Antireward Model (CReAM) of Chronic Pain.
The  ﬁgure is a schematic overview of the chronic pain’s self-sustaining and progressively worsening nature. Acute pain activates dopamine transmission in the brain’s reward
and  motivational centers, whereas prolonged periods of pain produce the opposite effect (within system adaptation) clinically manifested by anhedonia and diminished
motivational/incentive salience of natural reinforcers, that is to say the Reward Deﬁciency State (RD). Allostatic adjustment (processes that attempt to normalize the stress
on  the system) to excessive dopaminergic trafﬁcking in response to recurrent pain leads to a between system adaption involving the central and basolateral amygdala nuclei,
the  bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brain stem, the hippocampus and the Hb that in concert contribute to massive surges
of  CRF, norepinephrine, glutamate and dynorphin leading to the Anti-Reward State (AR) (see text). Thus, recurrent pain or ongoing pain may  contribute surges of these
stress-related chemicals. While stressogenic CRF and norepinephrine inﬂux contribute to the subjective sense of stress and similar negative affective states and dynorphin
further  worsens the anhedonia associated with the RD, glutamatergic sensitization promotes overlearning of the motivational salience of pain, analgesia and cues that predict
the  onset or severity of pain so that pain is constantly perceived to be worse than expected (viz., catastrophizing). These effects result in an unstable positive feedback loop
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(herein the combined reward RD and AR model (CReAM) drives further enhancem
he  buildup of the allostatic load that is unchecked by physiological negative feed
utcomes of chronic pain (i.e., intractability). (+) Signs represent stimulation.
.1. The reward-aversion continuum
Dopaminergic neurons in the ventral tegmental area (VTA)
nd their projections into the Nucleus Accumbens (NAc) com-
rise a putative ‘homeostat’ (Goldstein and McEwen, 2002) that
ompares hedonic information with a pre-set point. Speciﬁcally,
eward signals in the brain motivate actions that increase the prob-
bility that the behavior will be repeated in the future, whereas
versive signals inhibit actions that are likely to result in fruit-
ess pursuits or in painful consequences (Wickens, 2008). The
pponent-process theory (OPT) of emotion postulates that hedonic
one is derived from valuationally opposite reward and aversion
rocesses (Solomon and Corbit, 1973, 1974) mediating hedonic
omeostasis viz., equilibrium of emotional and motivational states.
or example, evocation of fear may  in turn contribute to posi-
ive emotions as is the case for roller coasters, automobile racing,
kydiving and horror movies or ‘traumatic bonding’ developed
y victims toward their tormentors i.e., “Stockholm syndrome.”
Cantor and Price, 2007).f pain and thus contributes to progressive worsening of the clinical condition and
echanisms leading to a diseased condition of the brain to the point of end-stage
Pain and reward are opponent processes (Becker et al., 2012),
but the latter is usually eclipsed by the former, so that the sense of
euphoria only becomes noticeable with the cessation of a painful
condition. The inter-subject variability regarding the proponent-
opponent processes interactions may  be quite substantial, and a
reverse situation is also possible. For example, in the extreme case
of algophilia, pain can be experienced as pleasant. Masochistic
and/or sadomasochistic behaviors occur with some frequency in
the population and are associated with generally adaptable psy-
chosocial functioning. Conversely, self-mutilating acts in patients
with borderline personality disorder, trichotillomania and excori-
ation disorder (American Psychiatric Association, 2013) highlight
the fact that pain and pleasure are not only opposites on a contin-
uum, but may  also be properties of a hedonic pain control system
with negative feedback processes.
A key feature of the OPT is that repeated activation of one process
results in a progressive weakening of that process and strength-
ening of the opponent process. Based on this concept, Koob and
colleagues advanced a model of the neurobiological basis of addic-
tion that emphasizes the close interface between the reward and
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Fig. 2. Top: interface of Reward and Anti-Reward Circuitry. Reward and anti-reward neurobiological systems are formed from hierarchically organized corticolimbic regions
along  with the clusters of hypothalamic and brainstem nuclei. The central nodes in the respective systems, namely the nucleus accumbens (NAc) and the Hb also constitute
their  major interface. The meso-accumbens dopamine pathway, extending from the ventral tegmentum (VT) of the midbrain to the forebrain regions such as the NAc,
amygdala and medial prefrontal cortex (mPFC), is the crucial component of the brain reward and reinforcement system that purportedly mediates in the maintenance of
hedonic  homeostasis. The habenula, an epithalamic nucleus with projections from the spinothalamic tract and to the periaqueductal gray matter (PAG), is a brain region
with  integrated sensory, emotional and motivational functions that modulates pain intensity, aversion and motor responses. Increased dopamine neurotransmission from
the  ventral tegmentum to the NAc is associated with euphorogenic responses to both natural rewards and to drugs of abuse. The habenula, on the other hand, opposes
this  action by providing inhibitory tone to dopamine neurons (with the input from other areas of the corticolimbic limbic system and basal ganglia) via interpeduncular
and  rostromedial tegmental nuclei projections, resulting in decreased dopamine transmission in the NAc and in the medial prefrontal cortex (mPFC), clinically visible as
decreased motivation and anhedonia. The functional reciprocity between NAc and Hb is also evident in the increase of the latter’s ﬁring to absence of an expected reward
or  to predictors of no-reward and the decrease of their ﬁring when an expected reward occurs. Recurrent dopaminergic trafﬁcking consequent to pain eventually results in
hypodopaminergic reward deﬁciency state in the NAc and in the mPFC and eventually gives rise to the between-system anti-reward adaptation, recruiting the Hb along with
the  central and basolateral amygdala nuclei, the bed nucleus of the stria terminalis, the lateral tegmental noradrenergic nuclei of the brainstem, the hypothalamic supraoptic
nucleus and the hippocampus that in concert contribute to massive outpouring of stressogenic corticotropin releasing factor (CRF), norepinephrine and dynorphin manifested
in  negative affective states, anhedonia and enhanced motivational salience attributed to pain and to relevant cues. Other major neurotransmitter systems contributing to
aversive anti-reward states including serotonin and acetylcholine are regulated by the Hb via respective raphe nuclei, locus coeruleus and nucleus of Meynert. Thus, the NAc
and  Hb are involved in reinforcement and are interconnected with the major brain regions involved in the modulation of pain, stress and emotions. As such, down regulation
of  reward circuitry in conjunction with sensitization of anti-reward structures contributes to the transition from the controlled pain situation to intractable and escalating
painful  states accompanied by emotional anguish.
Bottom: connectivity Maps for the Accumbens and for the Habenula. Reward and anti-reward circuitry has been examined recently through human neuroimaging experiments.
As  this literature grows, it has become increasingly possible to use “big data” methods such as text-mining, meta-analysis and machine-learning techniques to aggregate and
synthesize neuroimaging ﬁndings (Yarkoni et al., 2011). These methods provide a convenient way to illustrate and decode brain states as shown for the two model structures
below.
Nucleus  accumbens: automated Neurosynth meta-analysis of 329 studies of the feature “reward”. Lexigraphical features for NAc (MNI ± 10, 8, −10) include reward, rewards,
money, incentive, and addiction. The meta-analysis was  performed by automatically identifying all studies in the Neurosynth database that loaded highly on the feature
“reward”, and then performing meta-analyses to identify brain regions that were consistently or preferentially reported in the tables of those studies (see http://neurosynth.
org/) (Yarkoni et al., 2011).
Habenula: functional co-activation map  of 140 studies, and top lexigraphical features for Hb (MNI ± 4, −24, 2): monitoring, incentive, sadness, anticipation, disgust, and
no-go. Note, not enough studies have investigated anti-reward to produce an automated meta-analysis. Instead, we investigated what regions co-activate with the Hb, and
what  features are commonly associated with activation of the Hb region (Yarkoni et al., 2011).
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tress systems (Koob et al., 2014; Koob and Le Moal, 2005). The
uthors proposed that repeated drug-taking produces a decreased
unctioning of the reward systems, combined with a strengthening
f the so-called “anti-reward” systems that subserve the opponent
rocess of aversion. The former’s dysfunction is characterized by
 diminished capacity to experience joy, pleasure and motivation
i.e., RD), whereas the latter manifests as the subjective experi-
nce of aversion and stress (i.e., AR). The focus of this article is to
rgue that the combined RD-AR state, initially proposed as a model
f addiction, is also relevant for understanding chronic pain. This
elevance is supported by the key role of these processes in the
xperience of emotional pain (Koob et al., 2014) and the current
ecognition that physical and emotional pain connote anatomi-
ally overlapping and functionally congruent entities (Eisenberger,
012).
.2. Brain circuitry of reward, aversion, and the RD-AR state in
ddiction
Knowledge of the human reward- and anti-reward circuitry
omes in part from extensive investigations of rodent and primate
odels (Haber and Knutson, 2010; Hong et al., 2011; O’Doherty,
004; Thomas et al., 2001). While a major focus has been on the
ircuitry projecting from the VTA to the NAc (Russo and Nestler,
013), other brain regions e.g., amygdala and medial prefrontal
ortex (mPFC) that are connected to these two structures are also
nvolved, (Oades and Halliday, 1987; Salgado and Kaplitt, 2015; van
omburg and ten Donkelaar, 1991). Although the periaqueductal
ray (PAG) that is involved in a number of behaviors (Linnman et al.,
012) including pain modulation, is not classically part of reward
ircuitry, it is connected to many regions of the brain involved in
eward including the NAc (Ikemoto, 2010).
The NAc and habenula (Hb) are two respective nodes with
iscrete functions related to reward and aversion. The habenula,
ocated above the posterior thalamus, is divided into medial (MHb)
nd lateral (LHb) portions, and is primarily responsible for convey-
ng information from the limbic forebrain to the limbic midbrain
reas (Sutherland, 1982). The NAc, part of the ventral striatum, is
 critical element of the mesocorticolimbic system, a brain circuit
mplicated in reward, motivation, and salience attribution (Borsook
t al., 2013b). Recent optogenetic studies have shown that NAc
nd LHb participate in distinct dopaminergic circuits for eliciting
eward and aversion, respectively: a reward circuit from the lat-
rodorsal tegmentum to dopaminergic neurons in the VTA that
roject to the NAc, and an aversion circuit in which the LHb inhibits
opaminergic neurons in the VTA that project to the medial PFC
Lammel et al., 2012). This provides a potential neuroanatomi-
al model integrating reward (dopaminergic drive) and aversion
dopaminergic inhibition).
A number of studies have suggested that the Hb conveys an aver-
ive or ‘anti-reward’ signal (Stopper and Floresco, 2014), is involved
n negative prediction error processing (Salas et al., 2010), and in
 number of aversive states (Hennigan et al., 2015; Meye et al.,
015; Zuo et al., 2015). An inhibitory function may  be related to
he integration of reward expectancy, reward, or punishment as
oted in a functional magnetic resonance imaging study (fMRI)
tudy of the human Hb (Ullsperger and von Cramon, 2003). Both
Hb  and LHb neurons are excited by aversive stimuli or by the
mission of an expected reward (Hikosaka, 2010). LHb inactiva-
ion abolishes choice biases, making rats indifferent when choosing
etween rewards associated with different subjective costs and
agnitudes, but not larger or smaller rewards of equal cost (Stopper
nd Floresco, 2014). NAc activity is related to reward prediction
rror, in that it encodes the discrepancy between expected and
ctual reward outcome (Abler et al., 2006). Notably, altered neu-
al processing of prediction error is associated with a number ofavioral Reviews 68 (2016) 282–297 287
neurological and psychiatric diseases (Borsook et al., 2013a; Klein
et al., 2013), including chronic pain (Baliki et al., 2010).
Neurons from the LHb send indirect negative feedback signals to
dopamine cells in midbrain regions including the VTA via the ros-
tromedial mesopontine tegmental nucleus also (Balcita-Pedicino
et al., 2011). Thus, stimulation of the habenula leads to inhibition
of dopamine release in neurons in the VTA (Omelchenko et al.,
2009) and substantia nigra (Christoph et al., 1986). Speciﬁcally, LHb
neurons act on GABAergic neurons that inhibit dopamine release
(Barrot et al., 2012) thus pointing to this structure’s important role
in adapting or responding to rewarding or stressful stimuli. There-
fore, a higher engagement of the Hb reduces the probability of
phasic dopamine release in the reward system.
2.3. Reward circuitry and the RD state
A key brain mechanism of the rewarding effects of both natural
reinforcers as well as drugs of abuse is the increase in NAc dopamine
levels (Carlezon and Thomas, 2009). The intervening variable (see
Box 1 for deﬁnition) of subjective pleasure is sensed in the mPFC
(Berridge and Kringelbach, 2013; Goldstein and Volkow, 2002) that
exerts top down control of dopaminergic activity in the NAc via
the cortico-striatal segment of the cortico-striato-thalamo-cortical
circuit (Bimpisidis et al., 2013; Volkow et al., 2011). Increases or
decreases in the NAc’s dopamine concentrations prompt respective
habituation (Di Chiara et al., 2004) or sensitization (see deﬁni-
tion in Box 1) (Tremblay et al., 2002) in the key effector systems
consisting of pre- and post-synaptic dopamine receptors. Presy-
naptic dopamine transporters and enzymes involved in dopamine’s
synthesis and metabolism oppose and thereby balance abrupt
dopaminergic changes.
A reduction in dopamine levels, or hypodopaminergia, within
brain circuits mediating reward and motivation is the funda-
mental neurobiological change that underlies the RD state. This
hypodopaminergia may be innate (primary) or acquired (sec-
ondary, e.g., drug-induced). As noted above, this state is clinically
noticeable as a blunted capacity to enjoy or to experience pleasure
along with decreased motivation for natural rewards (Comings and
Blum, 2000; Volkow et al., 1997; Wise et al., 1978) including var-
ious activities that are driven by sociability, enthusiasm, esthetic
awareness, altruism and self-fulﬁllment.
2.4. Aversion/stress circuitry and the AR state
Regions involved in aversion and stress responses include the
central and basolateral amygdala nuclei, the bed nucleus of the stria
terminalis, the lateral tegmental noradrenergic nuclei of the brain-
stem, the hippocampus, and the Hb. The heightened sensitivity of
the aversion system that characterizes the AR state in addiction
is generated via massive surges of corticotropin-releasing factor
(CRF), norepinephrine, glutamate and dynorphin. The stressogenic
CRF and norepinephrine release contribute to the subjective sense
of stress and related negative affective states (e.g., fear, anxiety and
depression) while dynorphin further worsens the anhedonia asso-
ciated with the RD (Nestler and Carlezon, 2006). AR disrupts the
normal function of brain areas involved in reward/motivation and
stress processing, thereby reducing the impact of rewarding stim-
ulation and the ability to restrain stress responses. Although the AR
state may  possess some heuristic value in dissuading an individual
from engagement in hazardous situations (Henchoz et al., 2013),
the generated allostatic load is clearly dysfunctional as it promotes
isolation and social withdrawal, jeopardizing adequate coping and
adjustment.
As part of AR processes, initial homeostatic adjustments to
diminished tonic, resting state dopaminergic neurotransmission in
the NAc and prefrontal cortex produced by addictive drugs results
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n robust augmentations of phasic dopamine responses to stress
nd, via Pavlovian conditioning, to the relevant cues (Kalivas and
olkow, 2011; Volkow et al., 2011) and/or to interoceptive bodily
tates (Verdejo-Garcia et al., 2012). Prefrontal activations caused by
hese cues profoundly increase PFC glutamatergic output (Kalivas
nd Volkow, 2005) to an already hypofunctional NAc (Kalivas and
olkow, 2005), thus further decreasing dopaminergic activity with
onsequent worsening of the RD.
The progressive RD-AR adaptation is metaphorically termed
he “dark side of addiction” (Koob and Le Moal, 2005) as it is
nchecked by physiological negative feedback mechanisms, with
rugs (and/or natural rewards) providing only transient symp-
omatic relief while worsening neuroadaptations. It may  be quite
ifﬁcult to stop and/or reverse the developed vicious cycle as opi-
id analgesic drugs further worsen the RD and cause hyperalgesia
o the point of systematic collapse (Apkarian et al., 2004; Goldstein
nd Volkow, 2011) and subsequent end-stage outcomes such as
uicide (Fishbain, 1999; Gilbert et al., 2009).
Notwithstanding some negative affective states that may  be
ointly induced by RD and AR via hypodopaminergia and dynorphin,
here are important differences between these neuroadaptations,
ncluding neuroanatomical, neurochemical and key clinical mani-
estations (see Table 1). For instance, RD and AR jointly contribute
o negative affective states through dynorphin which in turn mod-
lates RD. On the other hand, other aspects of negative affective
tates such as anxiety or stress are mostly contributed by stresso-
enic hormones (CRF and norepinephrine).
. The RD-AR state in chronic pain
.1. Chronic pain and RD/hypodopaminergia
Patients with chronic pain exhibit certain psychopathological
nd clinical features in common with addiction. Both pain (Wood,
008; Wood et al., 2007) and opioids (Tanda et al., 1997) activate
opamine transmission in the brain reward circuitry, including the
Ac, whereas prolonged periods of pain or opioid drug consump-
ion produce the opposite effect (Wiech and Tracey, 2013) viz., RD
Assogna et al., 2011). Activation of mesolimbic reward circuitry,
ncluding the NAc, occurs with both acute pain and pain relief
Becerra et al., 2013; Navratilova et al., 2012); the latter may  reﬂect
he evocation of the opponent process.
Evidence supporting a hypodopaminergic state in chronic pain
omes from both preclinical (Niikura et al., 2010) and clinical
Hipolito et al., 2015; Kasahara et al., 2011; Loggia et al., 2014;
cDougle et al., 2015) data. Pain syndromes that have shown
ltered dopaminergic processing include burning mouth syndrome
Hagelberg et al., 2003), atypical facial pain (Hagelberg et al., 2003),
nd ﬁbromyalgia (Wood et al., 2007). For example, in ﬁbromyal-
ia patients vs. healthy pain-free controls a marked blunting
n striatal dopamine release was evident following induction of
xperimental pain (Wood et al., 2007 17610577). The high inci-
ence of central pain (including neuropathic pain) in Parkinson’s
atients (Canavero, 2009; Defazio et al., 2008) suggests that pain
s a common symptom in patients with hypofunctional nigrostri-
tal dopaminergic pathways (Coon and Laughlin, 2012), and that
ow dopamine may  contribute to increased pain (Wood, 2008).
ven among seemingly healthy individuals, low dopamine receptor
vailability is associated with enhanced pain responses (Pertovaara
t al., 2004). Speciﬁc polymorphisms in the dopamine transporter
ene (DAT-1) convey a high pain sensitivity stemming from a hypo-
unctional dopaminergic system (Treister et al., 2009). In healthy
uman volunteers, dopamine depletion (i.e., primary or secondary
ypodopaminergia − see Box 1) inﬂuences pain affect and not
ensory aspects of acute painful stimuli (Tiemann et al., 2014),avioral Reviews 68 (2016) 282–297
supporting the idea that in chronic pain, hypodopaminergia tar-
gets changes in affective states contributing to centralization of
pain. Hence, whereas in healthy individuals low dopamine (primary
or secondary, see Box 1) is associated with enhanced pain sen-
sitivity, chronic pain may  further decrease dopaminergic activity
through a feed-forward interaction (i.e., positive feedback; see Box
1) compromising both sensory and affective/cognitive processes
(Jarcho et al., 2012). In addition, dopamine is involved in descending
inhibitory modulation of pain transmission, which is an additional
link between hypodopaminergia and chronic pain (Potvin et al.,
2009).
Decreased levels of tonic dopamine result in increased sensi-
tivity of remaining dopamine neurons (Grace, 1991; Pucak and
Grace, 1991) and heightened phasic dopamine release. The dimin-
ished dopaminergic tone contributes to the increased sensitivity of
pain patients to emotional stimuli, somewhat similar to the phe-
nomenon of denervation hypersensitivity (see Box 1 for deﬁnition).
3.2. Chronic pain and AR/stress
The recruitment of stress and emotional systems as a result of
excessive activation of the reward system in response to recur-
rent pain may  lead not only to low detection capability for natural
rewards within the dopaminergic system (i.e., RD) but also to a
between-system adaption of heightened sensitivity to aversion and
stress, viz., the AR state. There are several lines of evidence that
link chronic pain to AR. On the psychophysiological level, AR in
pain patients is evident via their hypersensitive responses to con-
ditioned stressful stimuli (Marcinkiewcz et al., 2009; Miguez et al.,
2014). Clinically, stress is an integral part of the chronic pain syn-
drome (McEwen and Kalia, 2010; Neeck and Crofford, 2000). Pain
patients exhibit heightened levels of stress and arousal (Thieme
et al., 2006) and stress also plays a key role in exacerbations of
pain symptomatology (Finan and Smith, 2013; Lauche et al., 2013).
Furthermore, an exaggerated sympatho-adrenal tone as evidenced
by increased heart rate (Chalaye et al., 2013), norepinephrine con-
centrations (Buscher et al., 2010) (Buvanendran et al., 2012), and
skin conductance (Bonnet and Naveteur, 2004) are frequent clinical
ﬁndings in chronic pain patients (Currie and Wang, 2004). Also, the
CRF receptor type 1 is implicated in visceral hyperalgesia (Larauche
et al., 2012), while heightened CRF cerebrospinal ﬂuid concentra-
tions tend to parallel both sensory and affective pain components
(McLean et al., 2006).
3.3. Reward/aversion circuitry of NAc and Hb: role in chronic pain
Stimulation of the Hb has been reported to produce analgesia in
a model of acute pain, the formalin test (Cohen and Melzack, 1986).
However, we  are unaware of similar studies in a chronic pain model,
and a pain inhibitory effect would be difﬁcult to interpret within the
context of a role in AR. Indeed, the literature is far from unambigu-
ous on this account and is still evolving. In fMRI studies, this brain
region is activated by acute pain in healthy volunteers (Shelton
et al., 2012) and is tonically activated in patients with chronic pain
(Erpelding et al., 2013). Importantly, pain-induced alterations in
functional connectivity of the Hb improve with analgesic therapy,
suggesting that resolution of chronic pain improves Hb’s communi-
cation with the frontal and brainstem limbic regions (Shelton et al.,
2012). Functional imaging in central pain thalamic stroke patients
implicated Hb lesions in the onset and exacerbation of chronic pain
(Sprenger et al., 2012). Both animal (Li et al., 1993; Xie et al., 1998)
and human (Shelton et al., 2012) studies have shown connections
between the Hb and the PAG, a region involved in pain modulation
(Basbaum and Fields, 1979). Efferent projections from the LHb may
involve a pathway to the dorsal reticular nuclei and activation of
this pathway may  produce inhibition of avoidance or escape perfor-
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Table  1
Characteristics of reward deﬁciency and anti-reward processes.
Characteristic Reward deﬁciency Anti-reward
Type of neuroadaptation Within system Between systems
Neuroanatomy Mesolimbic dopaminergic circuitry,
including dopamine terminal ﬁelds
(e.g., the striatum, amygdala, and
Prefrontal Cortex (PFC))
Extended amygdala (basolateral
amygdala, bed nucleus of the stria
terminalis & lateral tegmentum),
hippocampus & habenula
Neurochemistry ↓dopamine receptors, ↑dopamine
transporters &
↓  dopamine synthesis
↑ cAMP Response Element Binding
(CREB) protein,
↓ tonic dopamine & ↑ long-term
depression
↑ in dynorphin, norepinephrine,
corticotropin-releasing factor &
glutamate
Reciprocal interactions ↑ stress as it is not buffered by reward Dynorphin contributes to reward
deﬁciency
Clinical  signiﬁcance ↓ in positive reinforcement of addictive Avoidance of potentially harmful
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Clinical manifestation Anhedonia 
ance depending on the serotoninergic receptor subtype activated
Pobbe and Zangrossi, 2010).
Activation of the NAc has been observed with both acute
Becerra et al., 2001) and chronic (Baliki et al., 2013) pain. A signif-
cant role for the region in chronic pain has subsequently emerged
n human imaging studies (Baliki et al., 2010), including studies
uggesting a role in altered sensory processing (e.g., allodynia (Ren
t al., 2016)) in chronic pain, and, more importantly, in predicting
ain chroniﬁcation (Baliki et al., 2012). In an animal model of post-
urgical pain, pain relief seems to produce activation of dopamine
eurons in the VTA and to increase dopamine release in the NAc
Navratilova et al., 2012). In addition, activation of mesolimbic
opamine neurons in the VTA that project to the NAc, plays an
mportant role in mediating the suppression of tonic pain (Altier
nd Stewart, 1999). LHb stimulation inhibits dopamine neurons (Ji
nd Shepard, 2007). The interactions between the reward and anti-
eward networks (central nodes in NAc and Hb, respectively) are
ikely the reason why deep brain stimulation (DBS) in the treatment
f resistant depression appears to be effective both when electrodes
re placed in the NAc as well as when placed in the Hb (Schlaepfer
nd Bewernick, 2013). Fig. 2 is a summary of interactions between
he NAc and Hb and connections between these regions and others
n the brain based on Functional Connectivity Mapping.
The above two structures do not exist in isolation. They are
ather embedded within a complex network of interrelated sys-
ems, each of which exhibits a unique function within the context
f chronic pain. For instance, a decrease in dopamine activity
i.e., hypodopaminergia) underlying RD can promote an AR state
ia potentiation of glutamatergic neurotransmission (Kalivas and
olkow, 2005). In support of this notion, the administration of neu-
oleptics can produce an aversive state in human patients (Bruun,
988; Naber, 1995). Furthermore, animal research indicates that
he inhibition of the dopamine system through pharmacological
r optogenetic means induces aversion and anxiety (Ilango et al.,
014; Liu et al., 2008; Sanberg, 1989). Electrophysiological studies
eport decrease in punishment during phasic suppression of ﬁring
n dopamine neurons (Schultz et al., 1997). Thus, reduced dopamine
ctivity may  produce both RD and AR states, which evoke additional
nteractions with other brain systems and/or with each other in a
downward spiral’ manner to exacerbate chronic pain.
. General model of RD-AR in pain
entralization/chroniﬁcation
The general conceptual model is schematically outlined in Fig. 3
nd summarized in Table 2. Chronic pain disrupts the normalsituations (e.g., pain, fear & losses)
Hyperkatifeia, craving &
compulsivity
function of the structures involved in stress and reward, deﬁning
two interrelated patterns of brain alterations, namely RD and AR.
These changes may  be complemented by genetic, epigenetic or dis-
ease status, and contribute to the ‘failed state’ of brain function
in chronic pain, adding to the severity of comorbidities and pain
chroniﬁcation (see Box 1). We have previously termed such changes
as the centralization of pain (Borsook et al., 2013c) (see below).
Here, we  suggest that the combination of alterations in the normal
function of Reward and Anti-Reward brain systems provides the
basis for pain centralization (see Box 1). Below we integrate con-
cepts based on these systems, including interactions between RD
and AR function, and provide clinical examples of comorbid condi-
tions (i.e., addiction, depression) or innate differences in hedonic
tone that may  either be exacerbated by pain centralization, or that
may  exacerbate pain centralization on the basis of CReAM (see
Fig. 4).
4.1. Pain and addiction
Cross sensitizing drugs (Cunningham and Kelley, 1992) may be
a mechanism involved in the complex interactions of chronic pain
and opioid-induced increases in pain i.e., opioid-induced hyper-
algesia (Angst and Clark, 2006) or the chroniﬁcation of pain with
opioid use as exempliﬁed in migraine (Bigal and Lipton, 2009). The
concept of cross-sensitization described in the addiction literature
typically refers to a situation where prior exposure to one stim-
ulus (e.g., drug) increases subsequent response to itself (Angrist
and Gershon, 1970; Post et al., 1982; Satel et al., 1991; Strakowski
et al., 1996), and to a different stimulus e.g., stress; (Goeders, 2003;
Southwick et al., 1999; Yehuda and Antelman, 1993). The reverse
can also occur, that is the enhancement of drug (Antelman et al.,
1980; Sorg and Kalivas, 1991) and stress effects (Goeders, 2003;
Southwick et al., 1999; Yehuda and Antelman, 1993) following prior
stress exposure. The sensitized stress responses in chronic pain may
thus confer greater motivational salience to pain-related cues, i.e.,
cross-sensitization (Rome and Rome, 2000), and thus may  increase
opioid analgesic drug consumption, which further increases stress
and consequently enhances cue responsivity and an ensuing tran-
sition from an excessive drug intake to a bona ﬁde addiction.
Although it is hypothesized that addiction develops via nega-
tive reinforcement mechanisms viz., the drug is used to ameliorate
the averseness of pain and of accompanying negative emotional
states (Khantzian, 1997), we  propose an adaptation of this idea
in the form of a positive reinforcement hypothesis i.e., reward
deﬁciency and anti-reward processes enhance drug use through
ampliﬁcation of its rewarding and reinforcing properties (Elman
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Table 2
Interactions between brain regions reward, anti-reward and pain.
Brain regions Neurochemicals Role Clinical Manifestation
Reward Anti-reward Pain Reward Anti-reward Pain
Mesolimbic neurons
projecting from VT to
striatum including
NAc, amygdala & PFC
Dopamine Motivation, salience &
prediction error
Reward enhancement by
inhibiting Hb (Stamatakis
et al., 2013).
Descending pain control;
pain salience, expectation
&  prediction of its
outcomes
Rewarding effects of
natural rewards as well as
of drugs of abuse
Subjective pleasure or
“high” (reward) that is
sought by drug users
Hypodopaminergia leads
to RD
Reward in the form of
pleasure buffers
anti-reward symptoms
– Hypodopaminergia
leads to hyperalgesia
–  Dopaminergic agents
(e.g., amphetamines)
possess analgesic
properties (Connor et al.,
2000)
Striatum  & PFC Glutamate Input to VT facilitates
activation of
reward-related
dopaminergic responses
(Tsai et al., 1995)
Mediation of
PFC–amygdala interactions
during stress-like i.e., AR
responses (Mora et al.,
2012)
Altered tonic/phasic
dopamine/
glutamate interaction is
caused by chronic pain
Memory of reward-action
association
Antagonism of glutamate
produces reward-like
effects (Krystal et al., 1998)
Glutamate is implicated in
depression, PTSD and in
other stress-related
conditions (Dunlop et al.,
2012; Hasselmann, 2014)
Overlearning of the
motivational signiﬁcance
of  cues that predict the
onset or severity of pain so
that pain is constantly
perceived to be worse than
expected i.e.,
catastrophizing.
Scattered network:
NAc, VTA, ventral
pallidum, nucleus of
the solitary tract,
parabrachial nucleus,
amygdala &
supraoptic nucleus
 Opioids Hedonic aspects of reward
(i.e., pleasure)
Dynorphin decreases
dopamine release (Krebs
et al., 1994)
Descending pain control;
analgesia
Addiction to opioid
analgesics
Dynorphin elicits
stress-like, AR symptoms
(Berke and Hyman, 2000)
Excessive opioid drugs’
synergism with pain in
creation CReAM (see Fig. 2)
The  habenula, central &
basolateral amygdala
nuclei, the bed
nucleus of the stria
terminalis, the lateral
tegmental
noradrenergic nuclei
of the brainstem, the
hippocampus raphe
nuclei, locus
coeruleus & nucleus
of Meynert (Elman
et al., 2013)
CRF, norepinephrine,
dynorphin, serotonin and
acetylcholine
Habenula inhibits activity
of mesolimbic
dopaminergic neurons
Up-regulation in the limbic
structures secreting CRF,
norepinephrine & other
hormones
Potential utility of not yet
approved adrenergic,
kappa and CRF antagonists
for pain management
AR processes enhance drug
use  through ampliﬁcation
of its rewarding and
reinforcing properties
(Elman et al., 2002)
Negative affective states Pain-related fear, anxiety
and depression
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Fig. 3. Progression from homeostasis to allostatic load and the spiraling distress cycle.
Schematic diagram of potential mechanisms involved in the development of CReAM (RD + AR) in chronic pain patients. Pain disrupts the normal homeostatic function of the
structures involved in reward and aversion/stress processing thereby giving rise to potential competitive, independent (i.e., additive) or synergistic types of interactions. For
acute  or mild pain competition may  be the most notable one because opponent processes contribute to the self-limited nature by restoring the homeostatic equilibrium.
With  ongoing pain, analgesics may  be less effective and the counterbalance in the adaptive state is lost. In addition, because allostatic changes, reﬂected in the use of
analgesic agents, occur even when the treatment of pain is deemed adequate, the resultant allostatic load may be additive with that of the chronic pain (e.g., drive drug dose
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ascalations). Synergism may  occur when the recursive partly shared positive feed
hemselves (Upadhyay et al., 2010) resulting in a “spiraling distress cycle” whereb
rocesses may  further contribute to treatment resistance (to current pharmacother
t al., 2002). This results in an autonomous, self-sustaining feed-
orward loop whereby trivial pain or stress can mount escalating
opamine release in the striatum, priming catastrophizing and
urther escalating the “spiraling distress cycle” of chronic pain simi-
ar to addiction (Koob and Le Moal, 1997) This triggers the drive
o seek and consume drugs (i.e., craving), leading to secondary
rug-induced phasic dopaminergic bombardment (Grace, 2000)
hat eventually overpowers the homeostatic restraint (Koob and
e Moal, 2001) and gives rise to the CReAM.
It is also plausible that acute administration of opioid analgesic
rugs in chronic pain patients alleviates emotional numbing tem-
orarily by boosting the activity of the reward regions (Jakupcak
t al., 2010) while regular or habitual consumption leads to further
eward circuitry desensitization clinically manifested as emotional
umbing (Volkow et al., 2007; Wang et al., 2012). Consequently,
hronic pain may  become unbearable not only on a physical
evel but also on a psychosocial level. Patients must cope with
ebilitating pain and the associated stress it brings, to the point
f developing pseudo-addiction i.e., compulsive seeking of opi-
id drugs driven by the desire to try to ameliorate inadequately
reated pain or to avoid a feared opioid withdrawal (see Box 1);
he term thus describes drug-seeking behavior that occurs in a
ain-dependent manner, as an active coping strategy to alleviate
ndertreated pain, and is fully reversible. It is therefore distin-
uishable from the construct of addiction, which by deﬁnition
s compulsory, maladaptive and hedonistic in nature (Weissman
nd Haddox, 1989), and from and pseudo-opioid resistance (self-
eported pain despite adequate analgesia owing to unwarranted
nxiety about a feared opioid dose reduction) (Elman et al., 2011).ReAM loops are produced by both chronic pain and potentially by the analgesics
e is an ampliﬁcation of the aversive physical and emotional aspects of pain. Such
 in chronic pain.
However, it should be pointed out that there is an opposing lit-
erature noting that chronic pain patients are not more likely to
abuse opioids, particularly when preexisting psychological states
(i.e., depression and anxiety) are controlled for (Edlund et al., 2007;
Elman et al., 2011; Fishbain et al., 1992). Pain is thus associated
with respective deﬁcit and excess of reward, analgesia and stress.
If deﬁcits (sensory and emotional) can be corrected then individu-
als may  be protected from addiction (Elman et al., 2011). The same
is true with regard to stress.
4.2. Pain and depression
Depressive symptoms are considered a key emotional compo-
nent of chronic pain (Fishbain et al., 1997) and it is commonly
hypothesized that such sequelae are mostly related to reduced
motivation and anhedonia-like RD (Aguera-Ortiz et al., 2011;
Nestler and Carlezon, 2006). Consistent clinical ﬁndings of both
subjective (Blackburn-Munro and Blackburn-Munro, 2001) and
objective (Rouwette et al., 2012) stress markers in chronic pain
patients call for the adaptation of this idea in the form of the CReAM,
in other words, a state of dynamic interactions between RD and AR
causing spiraling deterioration of both pain and reward function.
Notably, patients with major depression, and no prior history of
pain, commonly present pain symptoms. This suggests endogenous
alterations in neural circuits resulting in the ‘add on’ phenotype (i.e.,
chronic pain).
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Fig. 4. Reward-antireward model (CReAM) in pain chroniﬁcation.
The ﬁgure shows the progressive changes that may  occur in the evolution of chronic pain that include differences in process that involved in homeostatic, allostatic and
allostatic load. (1) Under normal homeostatic conditions, there is a balanced interaction between circuitry involved in reward and aversion i.e., normal ability to like and
dislike; (2) Under allostatic conditions (e.g., acute pain) there is a stressor that is mitigated by an opponent process (e.g., analgesics) that results in the normalization of the
process i.e., pain −> pain relief; and (3) Under allostatic load, normative processes become disrupted such that antireward circuits dominate changes in brain processing in
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ith  the progression to chronic pain, there may  be: (a) a diminished dopaminergic
yndrome; and (b) increasing levels of chronic stress based on ongoing aversive con
.3. Pain catastrophizing
Catastrophizing is an emotional state with a sense of impend-
ng doom or negative outcome that is predictive of pain intensity,
isability and emotional distress (Edwards et al., 2006; Sullivan
t al., 2001). Pain catastrophizing is deﬁned as a negative cognitive
nd emotional response to pain involving elements of rumina-
ion, magniﬁcation and feelings of helplessness (Quartana et al.,
009). A number of experiential pain induction paradigms have
ound evoked responses and evoked connectivity that correlates
o the degree of pain catastrophizing. The ﬁrst study associat-
ng pain catastrophizing with brain functional responses (Gracely
t al., 2004) in ﬁbromyalgia patients has since been followed up by
everal investigations in both healthy subjects (Henderson et al.,
016; Seminowicz and Davis, 2006) and in clinical populations
Blankstein et al., 2010; Hubbard et al., 2014), where the anterior
nsula, anterior cingulate, and thalamus were consistently found
o correlate with pain catastrophizing. In women with chronic
ulvar pain, catastrophizing correlated to parahippocampal and
ubstantia nigra alterations (Schweinhardt et al., 2008). Further,
atastrophizing is associated with heightened reports of craving
f opioid analgesics in patients with chronic pain (Martel et al.,
014). There are, however, no studies to date directly linking pain
atastrophizing and endogenous dopamine or opioid levels.
Avoidance behavior is a dynamic response that is not only inﬂu-
nced by pain and associated responding but also by contextual
actors and competing goals such as obtaining a reward (Sheynin
t al., 2015). Reward sensitivity is a trait that predisposes to a vari-
ty of disinhibition disorders, including drug abuse and addiction processing and comorbid changes that may include depression, anxiety). Note that
over time (i.e., hypodominergic condition) that contributes to a reward deﬁciency
.
(Volkow et al., 2010). In chronic pain states, pain relief is a highly
rewarding stimulus (Navratilova et al., 2015), such that the goal
to avoid pain may  supersede patients’ valued life goals. There may
thus be a dual impact: persistent pain and stress reduce dopamin-
ergic transmission (making pleasant things less pleasant), and by
prioritizing pain avoidance over reward (for example not playing
golf or not picking up a grandchild for fear of pain), patients may
experience fewer rewarding situations altogether.
5. Treatment opportunities in CReAM
Consideration of CReAM may  give rise to novel therapeu-
tic strategies in chronic pain patients including pharmaco- and
psycho-therapies, brain-training or a combination of these. Impor-
tantly, the chosen strategies certainly need to be tailored the nature
of the pain condition with its severity and evolution (i.e., chroni-
ﬁcation). Innate differences in hedonic tone and responsivity may
alter the magnitude of RD (Blum et al., 2012a) and AR.
5.1. Opioid ineffectiveness/resistance
The use of chronic opioids in chronic pain is not effective in
all patients. In some conditions, including migraine, it may  lead
to disease chroniﬁcation (Bigal and Lipton, 2009), whereas in other
conditions it may  result in pain sensitization and/or addiction. Even
when effective in chronic pain, the efﬁcacy of analgesic drugs is
rarely greater than 30% (Backonja et al., 1998). One  underlying rea-
son may  be the effects of chronic opioids on brain function and
structure (Upadhyay et al., 2010). But it might also be related to
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heir effects on dopamine, contributing to RD or AR. Thus, analgesic
herapy of the proponent pain stimuli could further deteriorate RD
nd AR and actually worsen rather than improve the pre-existing
hronic pain condition. Changes in the mesolimbic dopaminergic
ircuitry induced by opioids, administered at doses exceeding the
omeostatic need for pain alleviation, may  be responsible for the
mpliﬁcation of “hyperkatifeia” or negative affective states and of
hysical pain itself (Elman et al., 2011; Shurman et al., 2010). Hence,
he rationale for the use of cognitive and behavioral strategies (e.g.,
ognitive restructuring, stress management and systemic desen-
itization) alongside non-addictive alternatives to opioids with
ubstantial analgesic properties.
.2. Pharmacotherapies for CReAM
Behaviorally, RD is characterized by anhedonia, numbing, apa-
hy and decreased motivation for normally rewarding objects and
oals. As such these processes are linked to diminished mesolim-
ic dopaminergic neurotransmission (Gardner, 2011; Solomon and
orbit, 1973), which may  be targets for psychopharmacological
ntervention (Gorelick et al., 2004; Schroeder et al., 2013). Cur-
ently there are safe and non-addictive pharmaceutical agents that
ay  restore dopaminergic function to improve RD-related symp-
oms. Proprietal is one example – an investigational nutraceutical
hat is composed of dopamine precursors with inhibitors of the
opamine-degrading enzyme catechol-O-methyl transferase. Such
gents may  provide therapeutic beneﬁts for patients with RD (Blum
t al., 2010; Blum et al., 1988; Miller et al., 2010; Trachtenberg and
lum, 1988).
Inasmuch as the within-system reward deﬁciency neuroad-
ptation mainly diminishes positive moods and motivations, the
etween systems anti-reward neuroadaptation ampliﬁed this effect
ia dynorphin on top of increasing negative affective states through
he CRF and noradrenergic input (Koob and Le Moal, 1997, 2001,
008). These perturbations could be ameliorated by the phar-
acological manipulation (not yet FDA approved) of kappa and
RF systems. Kappa antagonists that reportedly diminish stress-
nduced potentiation of drug reinforcement (McLaughlin et al.,
003), have anti-depressant activity (Mague et al., 2003) and
ay  inhibit the dynorphin-associated stress response (Land et al.,
008). It should be noted, however, that while kappa agonists,
ave an antinociceptive effect, they also have negative side effects
ncluding dysphoria (Chavkin, 2011). CRF receptor antagonists may
lso prove to be promising by diminishing the stress response
Bruijnzeel et al., 2010; Bruijnzeel et al., 2012; Carels and Shepherd,
977), which may  also stabilize aberrant learning mechanisms. Ele-
ations in stress hormones and neurotransmitters (e.g., cortisol)
epeatedly paired with stressful situations can become conditioned
ues and elicit aberrant behaviors and emotions (Elman et al., 2003)
e.g., drug seeking and catastrophizing). Anti-glutamatergic agents
ay  be effective analgesics (e.g., benzodiazepine), however, these
ubstances have a high potential for abuse. Indirect pharmacologi-
al manipulations of glutamatergic activity for pain relief in humans
ave been achieved with lamotrigine or topiramate (Wiffen et al.,
013), as well as newer agents including minocycline (Kapoor,
013).
Stress is a strong candidate for cross-reactivity with pain
Gibson, 2012). The neuroanatomical substrate for such an
ffect may  involve two  closely linked and interacting networks
viz., dopaminergic reward pathways and the extrahypothala-
ic  norepinephrine/CRF system). As discussed above, alterations
n the mesolimbic dopaminergic circuitry resulting from chronic
ain may  transform regular motivational processes into height-
ned incentive salience (see Box 1) assigned to pain and
nalgesia. Mesolimbic dopaminergic and extrahypothalamic nore-
inephrine/CRF systems are intimately linked; thus dopaminergicavioral Reviews 68 (2016) 282–297 293
antagonists block norepinephrine/CRF anxiogenic responses and
vice versa (Saigusa et al., 2012; Sommermeyer et al., 1995). Adverse
effects of typical anti-dopaminergic agents, which can be serious,
may  render them a less than optimal choice for the maintenance
of patients with chronic pain. Nonetheless, the use of atypical anti-
dopaminergics (acting on 5HT-2 and D2 receptors) may  reverse the
reward deﬁcit state (Green et al., 1999).
As noted above, part of AR relates to a hyper-noradrenergic pro-
ﬁle. Noradrenaline increases pain facilitation (Martins et al., 2013)
and drugs that inhibit noradrenaline may  enhance anti-nociception
(Burnham and Dickenson, 2013). Descending inhibitory processes
arise in multiple areas of the brain, including the anterior cingulate
cortex, and project to brainstem regions involved in the modulation
of pain (Jensen et al., 2009; Jensen et al., 2012; Mainero et al., 2011).
Thus, the rationale for the use of adrenergic antagonists relates
to diminishing noradrenergic drive associated with AR that may
produce, directly or indirectly, enhanced anti-nociception.
5.3. Brain modulation therapies for CReAM
Given that chronic pain may  alter neural networks though
CReAM-based changes, methods that counter these effects
could contribute to symptomatic relief via adaptive plasticity
(Karatsoreos and McEwen, 2011). Brain regions such as the NAc
or Hb are promising targets due to their signiﬁcant interconnec-
tivity with primary pain and reward circuitry. A salient example
of this can be gleaned from reports on deep brain stimulation of
the Hb in patients with apparently successful results in resistant
depression (Schneider et al., 2013). Unlike in the acute state, such
stimulation is clearly altering both afferent and efferent pathways
in a brain hub that connects forebrain to hindbrain (brainstem)
structures (Hikosaka, 2010; Shelton et al., 2012), many of which
are involved in pain processing. Newer transcranial magnetic stim-
ulation (TMS) techniques may  offer the potential to carry out deep
brain stimulation non-invasively (Spagnolo et al., 2013).
6. Conclusions
Chronic pain is a major problem affecting millions of people
around the world at the time when its predisposing factors, pre-
vention strategies, etiology, pathophysiology and treatment are far
from being fully elucidated. With this model considering the neu-
robiological overlap between pain processing and the reward and
motivational circuitry, we considered the aspects of pain that are
pertinent to the CReAM.
Pain chroniﬁcation (see Box 1) certainly depends on the pre-
morbid health of the relevant brain circuits (Baliki et al., 2012;
Mansour et al., 2013) as well as maladaptive processing of RD and
AR states. The combination of preclinical and clinical ﬁndings sug-
gests that pain, by its chronic nature, leads to a hypodopaminergic
condition in the reward circuitry, resulting in the diminution of
the hedonic tone, viz., RD. At the same time, chronic pain patients
become sensitized to stressful stimuli in conjunction with the AR
markers of enhanced CRF, norepinephrine, dynorphin and glu-
tamate (Elman et al., 2013). This contributes to the build-up of
the allostatic load (Borsook et al., 2012; Von Korff et al., 2009)
and alters incentive salience of pain and analgesia, thus leading
to catastrophizing, pseudo-addiction, pseudo-opioid resistance in
conjunction with further worsening of anhedonia (Li et al., 2013),
depressive symptoms (Danna et al., 2013) and similar negative
affective states arising in the context of the RD status. In connec-
tion with this, chronic pain may  be conceptualized as a member
of a potential group that may  encompass other neuropsychiatric
syndromes deﬁned by the CReAM (e.g., addiction and major depres-
sion).
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Thus our insights could have important implications for the
rimary and secondary prevention of chroniﬁcation of pain. If
eurobiological vulnerability factors can be identiﬁed, they might
e used to screen patients at risk for the development of such
ondition. Patients found to possess high vulnerability for the
evelopment of chronic pain owing to preexisting diminution in
eward and/or enhanced stress function might be counseled to
void excessive drug and stress exposure (primary prevention), or
argeted for early intervention even in the presence of mild pain
roblems (secondary prevention).
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